Preventing Venous Thromboembolism Following Orthopedic Surgery in the United States
- 17 May 2011
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 17 (6) , 640-650
Abstract
Clinical trials of anticoagulants often exclude special populations. We assessed the proportion of special populations in real-world orthopedic surgery and the incidence of venous thromboembolism (VTE)-related outcomes. Data on patients with hip (n = 11 483) or knee replacement (n = 19 390) were extracted from IMS’ PharMetrics Patient-Centric Database. There was high prevalence of patients aged ≥75 years (20.3%), CYP3A4-inhibitor use (21.5%), and chronic warfarin use (9.5%). Venous thromboembolism events were increased with each increasing year of age (hip: odds ratio [OR] 1.02, 95% confidence interval [CI] = 1.01-1.03; knee: OR 1.01, 95%CI = 1.00-1.02) and chronic warfarin use (hip: OR 1.56, 95%CI = 1.13-2.17; knee: OR 1.33, 95%CI = 1.03-1.72); in hip patients with renal insufficiency (OR1.61, 95%CI=1.11-2.36); and in knee patients with atrial fibrillation (OR 1.41, 95%CI = 1.06-1.88). Major bleeding was higher in hip patients with hepatic impairment (OR 21.99, 95%CI = 2.04-236.62), each increasing year of age (OR 1.08, 95%CI = 1.01-1.15), and chronic warfarin use (OR 7.11, 95%CI = 1.16-43.46). Special populations are prevalent in real-world orthopedic surgery, which may impact VTE-related outcomes.Keywords
This publication has 19 references indexed in Scilit:
- Burden of illness of hypertension among women using menopausal hormone therapy: a US perspectiveCurrent Medical Research and Opinion, 2010
- Inpatient thromboprophylaxis use in U.S. hospitals: Adherence to the seventh American College of Chest Physician's recommendations for at‐risk medical and surgical patientsJournal of Hospital Medicine, 2009
- Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiencyThrombosis Research, 2008
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Prevention of Venous ThromboembolismChest, 2008
- Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional studyThe Lancet, 2008
- Review of the rebound phenomenon in new anticoagulant treatmentsCurrent Medical Research and Opinion, 2006
- Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacementJournal of Thrombosis and Haemostasis, 2005
- Venous Thromboembolism According to AgeArchives of internal medicine (1960), 2004
- Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJournal of Thrombosis and Haemostasis, 2004